Table 2 MYCN data for disseminated tumour cells in the bone marrow and tumour material from relapse or progression

From: Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study

Pt. no.

Age at dx in months

INSS stage at dx

MNA in BM-DTCs at dx

Relapse/progression

Time to relapse/progression in years

Analysed relapse/progression material

MNA in relapse/progression

33

12

2a

No

No

39

13

4

No

No

41

13

3a

No

No

58

19

4

hetMNA

Yes

1

na

63

23

4

hetMNA

Yes

0, 7

na

66

26

4

hetMNAb

Yes

0, 8

na

82

46

4

hetMNAc

Yes

1

Liquor

hetMNAd

84

46

4

No

Yes

2, 4

DTCs

No

86

50

4

No

Yes

0, 3

na

89

57

4

No

Yes

1, 9

na

90

61

4

ne

Yes

7, 10, 11

Metastases

1. rel: hetMNA;

2. rel: no MNA;

3. rel: no MNA

97

93

4

No

Yes

2, 5

DTCs

No

99

171

4

No

Yes

0, 7

Tumour

No

11

5

4s

No BM

infiltration

Yes

2, 1

Tumour

MNA

48

14

3

No BM

infiltration

Yes

1, 2

Tumour

No

77

41

2

No BM

infiltration

Yes

0, 3

Tumour

No

78

42

4

No BM

infiltration

Yes

0, 5

Lung

metastasis

No

  1. MYCN status for 17 patients with either tumour-infiltrated bone marrows and MYCN FISH investigations and/or MYCN FISH-investigated tumour material from relapse or progression material
  2. BM bone marrow, DTC disseminated tumour cells, dx diagnosis, hetMNA heterogeneous MYCN amplification, INSS International Neuroblastoma Staging System, MNA MYCN amplification (homogeneous), na not available, ne not evaluated, Pt. no. patient number
  3. acytomorphologically, the bone marrows of these patients at diagnosis were free of tumour cells, however, immunofluorescence (GD2) and FISH positive
  4. bmajority of DTCs showed MNA
  5. c5 of 12 DTCs showed MNA
  6. d5 of 33 tumour cells with MNA